Where to buy Indian version of Maribavir

There is currently no "Indian version of Maribavir (Maribavir) generic drug". This is a very clear fact in the international drug market. Since the patent of this drug is still protected and countries have not yet opened up the production of generic drugs, the information on the market about the "Indian version" or "low-priced generic maribavivir" is mostly misleading or comes from unknown sources. Patients must be wary of the risks of counterfeit drugs. At this stage, the maribavivir available to domestic patients is The original research product has been included in China’s medical insurance, significantly improving its accessibility.

The main version circulating in domestic hospitals and pharmacies is the US version of original research maribavivir (200mg*56 tablets), with a market price of about 29,000 yuan. After being included in medical insurance, patients' out-of-pocket payment ratio is reduced, which effectively reduces the financial burden and makes the use of original drugs more popular. Since its indications are mainly for refractory CMV infections after transplantation, clinicians will conduct a detailed assessment based on the patient's virological manifestations, drug resistance and organ transplant type before issuing a prescription.

In overseas markets, the European version of maribavivir is also an original drug, and its price is usually higher than that of the domestic version, mainly due to factors such as higher European terminal selling prices, increased taxes and logistics costs, and exchange rate fluctuations. Therefore, when actually purchasing, patients will almost never choose to parallel import European drugs from overseas because the cost is much higher than the domestic price after medical insurance.

Some cross-border platforms and individual channels claim to provide “lower-priced drug sources,” but most such channels cannot prove that the quality of drugs is trustworthy, and they lack legal import qualifications, posing extremely high drug risks. Cytomegalovirus (CMV) infection may cause serious or even irreversible complications in transplant patients, so the use of drugs of unknown origin may lead to treatment delays with serious consequences.

Reference materials: https://www.livtencity.com/